Cogent Biosciences, Inc. has completed a public offering of $230 million aggregate principal amount of 1.625% Convertible Senior Notes due 2031, including the full exercise of the underwriters' over-allotment option for an additional $30 million. The Notes were issued under an indenture between Cogent Biosciences and U.S. Bank Trust Company, National Association, as trustee. The agreement includes provisions for special interest in the event of certain defaults, and outlines circumstances under which the principal amount becomes due, such as bankruptcy or significant financial judgments against the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-286158), on November 18, 2025, and is solely responsible for the information contained therein.